Abstract
Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.
| Original language | English |
|---|---|
| Pages (from-to) | 711-713 |
| Number of pages | 3 |
| Journal | Medical Science Research |
| Volume | 24 |
| Issue number | 10 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Anti-phospholipid antibodies
- Crohn's disease
- Thrombosis
- Ulcerative colitis
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Antiphospholipid antibodies in patients with inflammatory bowel disease. / Caccavo, D.; Greco, B.; Caradonna, L.; Leandro, G.; Bonomo, L.; Jirillo, E.
In: Medical Science Research, Vol. 24, No. 10, 1996, p. 711-713.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiphospholipid antibodies in patients with inflammatory bowel disease
AU - Caccavo, D.
AU - Greco, B.
AU - Caradonna, L.
AU - Leandro, G.
AU - Bonomo, L.
AU - Jirillo, E.
PY - 1996
Y1 - 1996
N2 - Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.
AB - Antiphospholipid antibodies (e.g. anticardiolipin antibodies; aCL) are frequently associated with thrombotic events. In view of the evidence that thrombotic phenomena may complicate inflammatory bowel disease (IBD), we have measured aCL in patients affected by ulcerative colitis (UC) (n = 30) and Crohn's disease (CD) (n = 22). We demonstrated that 6/30 (20%) of UC and 8/22 (36%) of CD patients showed increased levels of aCL (p <0.004 and p <0.0001, respectively, compared with healthy controls). aCL from IBD patients bound the corresponding antigen more efficiently in the presence of bovine serum which contained β2-glycoprotein I, a lipid-binding inhibitor of coagulation. aCL did not correlate either with disease activity or extent. No patient had clinical manifestations and/or a history of thromboembolism, which can perhaps occur without overt clinical signs. aCL could be a risk factor for intestinal thrombotic phenomena.
KW - Anti-phospholipid antibodies
KW - Crohn's disease
KW - Thrombosis
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=0029950333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029950333&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029950333
VL - 24
SP - 711
EP - 713
JO - Medical Science Research
JF - Medical Science Research
SN - 0269-8951
IS - 10
ER -